Skip to main content

Table 3 Adjusted odds ratiosa (aORs) and 95% confidence intervals (CIs) for prescribing vs. not prescribing a drug based on receiving any payment vs. no paymentb

From: Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

 Drug of Uncertain Medical Benefit

aOR (95%CI)

Brand Control

aOR (95%CI)

Generic Control

aOR (95%CI)

Lovastatin ER

1.28 (0.82–2.80)

Rosuvastatin

1.80 (1.74–1.86)

Lovastatin

0.78 (0.76–0.80)

Almotriptan

1.36 (0.83–2.23)

Rizatriptan

0.93 (0.68–1.27)

Sumatriptan

0.74 (0.50–1.10)

Amlodipine+olmesartan

1.42 (1.36–1.49)

Telmisartan

1.18 (1.08–1.29)

Irbesartan

0.74 (0.70–0.78)

Ibuprofen+famotidine

1.10 (0.76–1.60)

Celecoxib

1.85 (1.80–1.89)

Ibuprofen

0.79 (0.77–0.81)

Saxagliptin+metformin

1.50 (1.42–1.59)

Sitagliptin

1.45 (1.42–1.48)

Metformin

0.80 (0.72–0.89)

Naproxen+esomeprazole

1.45 (1.25–1.68)

Celecoxib

1.61 (1.57–1.65)

Naproxen

0.74 (0.72–0.76)

  1. aAdjusted for gender, specialty, region, therapeutic category and overall prescribing volume
  2. bEach drug was analyzed in a separate model
  3. p-value <0.05 are presented in boldface